Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruzaika Cader

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
British Journal of Hospital Medicine (London, England : 2005)|July 30, 2024
Advances in primary glomerulonephritisBetsy Ellison, Ruzaika Cader, Lisa Willcocks
Oxford Medical Case Reports|August 26, 2016
An uncommon complication of atrial fibrillationMichael Mallouppas, Christos Christopoulos, Will Watson, et al.
BMC Nephrology|August 7, 2024
A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)Lisa C Willcocks, Wendi Qian, Ruzaika Cader, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
British Journal of Hospital Medicine (London, England : 2005)|July 30, 2024
Advances in primary glomerulonephritisBetsy Ellison, Ruzaika Cader, Lisa Willcocks
Oxford Medical Case Reports|August 26, 2016
An uncommon complication of atrial fibrillationMichael Mallouppas, Christos Christopoulos, Will Watson, et al.
BMC Nephrology|August 7, 2024
A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)Lisa C Willcocks, Wendi Qian, Ruzaika Cader, et al.
Pageof 1